Second-generation AAV vectors have been altered and provided with unique tissue-specific promoters to reduce immunogenicity and will continue to provide long-lasting BDNF expression, subsequently aiding in neuronal connectivity and promoting survival across multiple models of neurodegenerative disease [324]. Here, BDNF is linked to neurodegenerative disease.